Back to top

BorgWarner (BWA) Q1 Earnings Beat Estimates, Gains Y/Y

Read MoreHide Full Article

BorgWarner Inc. (BWA - Free Report) offers efficient and clean technology solutions, essential for combustion, hybrid and electric vehicles. The company reported adjusted earnings of $1.10 per share in first-quarter 2018, beating the Zacks Consensus Estimate of $1.03. Adjusted earnings increased from 91 cents reported in the year-ago quarter.

Revenues

BorgWarner logged revenues of $2.78 billion, beating the Zacks Consensus Estimate of $2.63 billion. The revenue figure for first-quarter 2017 was $2.41 billion.

Estimate Trend & Surprise History

Investors should note that stock has witnessed an upward trend in the Zacks Consensus Estimate for annual earnings over the last seven days.

The company delivered positive earnings surprises in the trailing four quarters, leading to an average beat of around 7.6%.

BorgWarner Inc. Price and EPS Surprise

Zacks Rank

BorgWarner currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

We have highlighted some of the key stats from this Michigan-based company’s earnings announcement below:

Key Stats/Developments to Note

For second-quarter 2018, the company envisions net earnings to lie within the range of $1.09 to $1.11 per share. Moreover, it expects net organic sales growth of 7-9% compared with net sales of $2.39 billion in the year-ago quarter. The acquisition of Sevcon will contribute $50 million in net sales.

For full-year 2018, the company reaffirmed organic growth guidance. It projects net sales of around $10.77-$10.94 billion, which translates into an organic growth rate of 5-7%. Further, the company expects net earnings within the range of $4.30-$4.40.

Furthermore, BorgWarner expects the positive impact of foreign currencies on the appreciation of the Euro and Chinese Yuan of $405 million.

Check back later for our full write up on BorgWarner’s earnings report!

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline. 

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


BorgWarner Inc. (BWA) - free report >>